Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00821977 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 338
- Enrollment target
- 20
- Study locations
NCT00821977 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by Novartis. The registered enrollment target is 338 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT00821977, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 338 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vildagliptin
Study Locations (20)
California
- Sall Research Medical Center - Artesia
- Associated Pharmaceutical Research - Buena Park
- Providence Research - Burbank
- Burbank - Lovelace Scientific Resources, Inc. - Burbank
- Lucita M. Cruz, M.D., Inc. - Norwalk
- California Research Foundation - San Diego
- Ritchken and First MDs - San Diego
- San Diego Sports Medicine Research and Family Care - San Diego
- Crest Clinical Trials - Santa Ana
Arizona
- Horizon Clinical Research Associates, PLLC - Gilbert
- Vista Medical Research, Inc - Mesa
- Clinical Research Advantage - Mesa
- Hope Clinical Research - Phoenix
- Anasazi Internal Medicine - Phoenix
- Tatum Ridge Internal Medicine - Phoenix
- Paradigm Clinical - Tucson
- Tucson Clinical Research - Tucson
Arkansas
- Medical Investigations, Inc. - Little Rock
- Paul W. Davis, MD - Pine Bluff
Alabama
- Advanced Clinical Research - Pell City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00821977
The ClinicalTrials.gov registry entry for NCT00821977 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00821977 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00821977 about?
NCT00821977 is a clinical study titled "Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes". This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.
What is the current status of trial NCT00821977?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 338 participants. The study started on 2008-11. Estimated completion is 2010-10.
What conditions does trial NCT00821977 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00821977?
The interventions under investigation include: Placebo (DRUG), Vildagliptin (DRUG).
Who is sponsoring clinical trial NCT00821977?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00821977 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.